AAAAAA

   
Results: 1-16 |
Results: 16
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
Authors: Stoddart, CA Liegler, TJ Mammano, F Linquist-Stepps, VD Hayden, MS Deeks, SG Grant, RM Clavel, F McCune, JM
Citation: Ca. Stoddart et al., Impaired replication of protease inhibitor-resistant HIV-1 in human thymus, NAT MED, 7(6), 2001, pp. 712-718
Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues
Authors: Penn, ML Myers, M Eckstein, DA Liegler, TJ Hayden, M Mammano, F Clavel, F Deeks, SG Grant, RM Goldsmith, MA
Citation: Ml. Penn et al., Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues, AIDS RES H, 17(6), 2001, pp. 517-523
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting
Authors: Miller, V Vandamme, AM Loveday, C Staszewski, S Lundgren, J Youle, M Ait-Khaled, M Boucher, C Brun-Vezinet, F Dedes, N Giaquinto, C Hertogs, K Houyez, F Perrin, L Pillay, D Schmit, JC Schuurman, R Lange, J Banhegyi, D Biondi, G Broekhuizen, A Bush-Donovan, C Camacho, R Carlier, H Clavel, F Clotet, B Clumeck, N Colebunders, R De Clerq, K De Jaegher, JJ De Schrijver, G De Smet, K Hall, W Harrigan, R Hatzakis, A Hellmann, N Hoetelmans, R Holtzer, C Katlama, C Larder, D Loriaux, E McCreedy, B Mulcahy, F Opravil, M Phillips, A Ruiz, N Shulse, E Sonnerborg, A Soriano, V Steel, H Vella, S Williams, A
Citation: V. Miller et al., Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting, AIDS, 15(3), 2001, pp. 309-320
Changes in human immunodeficiency virus type 1 populations after treatmentinterruption in patients failing antiretroviral therapy
Authors: Hance, AJ Lemiale, V Izopet, J Lecossier, D Joly, V Massip, P Mammano, F Descamps, D Brun-Vezinet, F Clavel, F
Citation: Aj. Hance et al., Changes in human immunodeficiency virus type 1 populations after treatmentinterruption in patients failing antiretroviral therapy, J VIROLOGY, 75(14), 2001, pp. 6410-6417
Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay
Authors: Trouplin, V Salvatori, F Cappello, F Obry, V Brelot, A Heveker, N Alizon, M Scarlatti, G Clavel, F Mammano, F
Citation: V. Trouplin et al., Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay, J VIROLOGY, 75(1), 2001, pp. 251-259
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
Authors: Picard, V Angelini, E Maillard, A Race, E Clavel, F Chene, G Ferchal, F Molina, JM
Citation: V. Picard et al., Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine, J INFEC DIS, 184(6), 2001, pp. 781-784
Discordant increases in CD4(+) T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: Role of changes inthymic output and T cell death
Authors: Lecossier, D Bouchonnet, F Schneider, P Clavel, F Hance, AJ
Citation: D. Lecossier et al., Discordant increases in CD4(+) T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: Role of changes inthymic output and T cell death, J INFEC DIS, 183(7), 2001, pp. 1009-1016
New techniques and methods in applied public health in oncology
Authors: May-Levin, F Clavel, F Monsonego, J Tristant, H Levy, L
Citation: F. May-levin et al., New techniques and methods in applied public health in oncology, B CANCER, 88(1), 2001, pp. 23-34
Phenotypic resistance to protease inhibitors in patients who fail on highly active antitetroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz
Authors: Piketty, C Race, E Castiel, P Belec, L Peytavin, G Si-Mohamed, A Gonzalez-Canali, G Weiss, L Clavel, F Kazatchkine, MD
Citation: C. Piketty et al., Phenotypic resistance to protease inhibitors in patients who fail on highly active antitetroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz, AIDS, 14(5), 2000, pp. 626-628
Retracing the evolutionary pathways of human immunodeficiency virus type 1resistance to protease inhibitors: Virus fitness in the absence and in thepresence of drug
Authors: Mammano, F Trouplin, V Zennou, V Clavel, F
Citation: F. Mammano et al., Retracing the evolutionary pathways of human immunodeficiency virus type 1resistance to protease inhibitors: Virus fitness in the absence and in thepresence of drug, J VIROLOGY, 74(18), 2000, pp. 8524-8531
Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
Authors: Race, E Dam, E Obry, V Paulous, S Clavel, F
Citation: E. Race et al., Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies, AIDS, 13(15), 1999, pp. 2061-2068
Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy
Authors: Piketty, C Race, E Castiel, P Belec, L Peytavin, G Si-Mohamed, A Gonzalez-Canali, G Weiss, L Clavel, F Kazatchkine, MD
Citation: C. Piketty et al., Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy, AIDS, 13(11), 1999, pp. F71-F77
Transmission of antiretroviral-drug-resistant HIV-1 variants
Authors: Yerly, S Kaiser, L Race, E Bru, JP Clavel, F Perrin, L
Citation: S. Yerly et al., Transmission of antiretroviral-drug-resistant HIV-1 variants, LANCET, 354(9180), 1999, pp. 729-733
Kinetics of antiviral activity and intracellular pharmacokinetics of humanimmunodeficiency virus type 1 protease inhibitors in tissue culture
Authors: Nascimbeni, M Lamotte, C Peytavin, G Farinotti, R Clavel, F
Citation: M. Nascimbeni et al., Kinetics of antiviral activity and intracellular pharmacokinetics of humanimmunodeficiency virus type 1 protease inhibitors in tissue culture, ANTIM AG CH, 43(11), 1999, pp. 2629-2634
Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
Authors: de la Carriere, LC Paulous, S Clavel, F Mammano, F
Citation: Lc. De La Carriere et al., Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity, J VIROLOGY, 73(4), 1999, pp. 3455-3459
Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
Authors: Dulioust, A Paulous, S Guillemot, L Delavalle, AM Boue, F Clavel, F
Citation: A. Dulioust et al., Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors, J VIROLOGY, 73(1), 1999, pp. 850-854
Risultati: 1-16 |